FWP / Forward Pharma A/S - ADR - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

FWP / Forward Pharma A/S / Rosetta Capital I, Lp - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea173546-13ga1rosetta1for.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value DKK 0.01 per share (Title of Class of Securities) 34986J 204 (CUSIP Number) December 31, 2022 (Date of Event which

Joint Filing Agreement dated as of February 14, 2023, by and among each of the Reporting Persons

EX-99.1 2 ea173546ex99-1forward.htm JOINT FILING AGREEMENT DATED AS OF FEBRUARY 14, 2023, BY AND AMONG EACH OF THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the beneficial ownership

As filed with the Securities and Exchange Commission on January 20, 2023 Registration No. 333-203313 Registration No. 333-261624 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 post-effective Amendment No. 1 FORM S-8 REGISTRAT

As filed with the Securities and Exchange Commission on January 20, 2023 Registration No.

As filed with the Securities and Exchange Commission on January 20, 2023 Registration No. 333-203313 Registration No. 333-261624 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 post-effective Amendment No. 1 FORM S-8 REGISTRAT

As filed with the Securities and Exchange Commission on January 20, 2023 Registration No.

As filed with the Securities and Exchange Commission on January 20, 2022 Registration No. 333-261626 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT UNDER THE S

POS AM 1 posam012023.htm FORM POS AM As filed with the Securities and Exchange Commission on January 20, 2022 Registration No. 333-261626 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Forward Pharma A/S (Exact name of registrant as specified in its charter) Not Applicable (T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36686 Forward Pharma A/S (Exact name of registrant as specified in its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 13, 2023 Commission File Number: 001-36686 Forward Phar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 January 13, 2023 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover

JOINT FILING AGREEMENT

EX-99.1 2 d408900dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned and each other person executing this joint filing agreement (this “Agreement”) agree as follows: (i) The undersigned and each other person executing this Agreement are individually eligible to use the Schedule 13G to which this Exhibit is attached and such Schedule 13G is filed on behalf of the undersigned and eac

FWP / Forward Pharma A/S / StepStone Group LP - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 28, 2022 Commission File Number: 001-36686 Forward Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 28, 2022 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cove

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 16, 2022 Commission File Number: 001-36686 Forward Pha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 December 16, 2022 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cove

Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review

EXHIBIT 99.1 Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European Patent Office (the “EPO”) has denied Forward’s petition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 6, 2022 Commission File Number: 001-36686 Forwar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 6, 2022 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDT?GTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2022 (Commission file number) Forward Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 9, 2022 Commission File Number: 001-36686 Forward Pharma A/S Østerga

? ? FORM 6-K ? SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 November 9, 2022 Commission File Number: 001-36686 Forward Pharma A/S ? ?stergade 24A, 1 1100 Copenhagen K, Denmark ? Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F o

Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statement of Financial Position as of June 30, 2022 and December 31, 2021

Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statement of Financial Position as of June 30, 2022 and December 31, 2021 ? Assets ? ? ? ? ? ? ? ? ? ? ? ? June 30, ? ? ? ? 2022 December 31, ? ? ? ? (Unaudited) ? 2021 ? ? Notes ? USD ?000 ? USD ?000 Non-current assets: ? ? ? ? ? ? Other non-current assets ? 3 3 Total non-current assets 3 3 P

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited interim condensed consolidated financial statements, including the notes thereto, included elsewhere in this Report on Form 6-K, as well as our Annual Report on Form

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 12, 2022 Commission File Number: 001-36686 Forward Ph

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 12, 2022 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cov

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 1, 2022 Commission File Number: 001-36686 Forward Pharma A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 July 1, 2022 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2022 (Commission file number) Forward Pharma A/S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 5, 2022 Commission File Number: 001-36686 Forward Pharma A/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 5, 2022 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover of F

Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Friday 20 May 2022 at 2:00 pm (CET). Name: Address: (Please use CAPITAL LETTERS) I/we hereby authorise by

Exhibit 99.2 Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Friday 20 May 2022 at 2:00 pm (CET). Name: Address: (Please use CAPITAL LETTERS) I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below: Please check off field A), B), C) or D):

If you wish to give proxy or vote by correspondence, please complete the proxy/voting by correspondence form. Please remember to sign and date the form. Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S wil

Exhibit 99.3 If you wish to give proxy or vote by correspondence, please complete the proxy/voting by correspondence form. Please remember to sign and date the form. Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S will be held on Friday 20 May 2022 at 2.00 pm (CET) at the company?s premises, ?stergade 24A, 1 st floor, 1100 Copenhagen K, Denmark. REQUES

Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Friday 20 May 2022 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copen

Exhibit 99.1 Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Friday 20 May 2022 at 2.00 pm (CET) at the company?s premises, ?stergade 24A, 1st floor, 1100 Copenhagen K, Denmark. AGENDA (a) The board of directors? report on the company?s activities in the past financial year. (b) Presentation and

SHARES AND VOTING RIGHTS AS PER 5 MAY 2022 * Voting rights cannot be exercised SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.01) NO. OF VOTES Ordinary shares 992,765.87 99,276,587 99,276,587 Outstanding shares 992,765.87 99,276,587 99,

Exhibit 99.4 SHARES AND VOTING RIGHTS AS PER 5 MAY 2022 * Voting rights cannot be exercised SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.01) NO. OF VOTES Ordinary shares 992,765.87 99,276,587 99,276,587 Outstanding shares 992,765.87 99,276,587 99,276,587 Own holding of shares* 0 0 0 Outstanding shares excluding own holding of shares 992,765.87 99,276,587 99,276,587 DocuSign Envelop

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2022 (Commission file number) Forward Pharma A/

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 28, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

Exhibit 12.1 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

Consent of EY Godkendt Revisionspartnerselskab, Independent Registered Public Accounting Firm.

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-261626) and Form S-8 (Nos. 333-203313 and 333-261624) of our report dated April 8, 2022, with respect to the consolidated financial statements of Forward Pharma A/S included in this Annual Report (Form 20-F) for the year ended Decemb

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

Exhibit 12.2 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respec

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the “Company”), on Form 20-F for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Claus Bo Svendsen, Chief Executive Officer, principal executive

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 22, 2022 (Commission file number) Forward Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 22, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

2 2.4 Ejerbogen føres af Computershare A/S (CVR - nr. 27088899). The register of shareholders is kept by Computershare A/S (Company Regis - tration (CVR) no. 27088899). 2.5 Aktierne er ikke - omsætningspapirer . Der gælder ingen indskrænkninger i akt

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDT?GTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

FWP / Forward Pharma A/S / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 5 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value 0.01 DKK per share (Title of Class of Securities) 34986J204 (CUSIP Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 27, 2022 (Commission file number) Forward Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 27, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

FORWARD PHARMA A/S

Exhibit 99.3 FORWARD PHARMA A/S ?stergade 24A, 1. 1100 Copenhagen K Denmark Tel. +45 33 44 42 42 Cell. +45 81 77 12 50 [email protected] www.forward-pharma.com Nasdaq:FWP VAT Number 28 86 58 80 Sent by e-mail: [?] [Holder of deferred shares] Copenhagen, 20 January 2022 DEPOSIT OF SHARES AGAINST ISSUE OF AMERICAN DEPOSITARY SHARES p Dear [?], We write to you in your capacity as a holder of def

FORWARD PHARMA A/S

Exhibit 99.1 FORWARD PHARMA A/S ?stergade 24A, 1. 1100 Copenhagen K Denmark Tel. +45 33 44 42 42 Cell. +45 81 77 12 50 [email protected] www.forward-pharma.com Nasdaq:FWP VAT Number 28 86 58 80 Sent by e-mail: [?] [Shareholder] Copenhagen, 20 January 2022 DEPOSIT OF SHARES AGAINST ISSUE OF AMERICAN DEPOSITARY SHARES Dear [?], We write to you in your capacity as shareholder in Forward Pharma A

FORWARD PHARMA A/S

Exhibit 99.2 FORWARD PHARMA A/S ?stergade 24A, 1. 1100 Copenhagen K Denmark Tel. +45 33 44 42 42 Cell. +45 81 77 12 50 [email protected] www.forward-pharma.com Nasdaq:FWP VAT Number 28 86 58 80 Sent by e-mail: [?] [Warrantholder] Copenhagen, 20 January 2022 DEPOSIT OF SHARES AGAINST ISSUE OF AMERICAN DEPOSITARY SHARES Dear [?], We write to you in your capacity as holder of warrants in Forward

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 20, 2022 (Commission file number) Forward Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 20, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

Forward Pharma Corporate Update (Nasdaq:FWP) January 3, 2022 2022© Forward Pharma A/S Forward - Looking Statements 2 2022© Forward Pharma A/S Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S

Exhibit 99.1 Forward Pharma Corporate Update (Nasdaq:FWP) January 3, 2022 2022? Forward Pharma A/S Forward - Looking Statements 2 2022? Forward Pharma A/S Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include, but are not limited to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 10, 2022 (Commission file number) Forward Pharma

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 10, 2022 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

December 21, 2021

December 21, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Forward Pharma A/S Registration Statement on Form F-3 Filed December 13, 2021 File No.

As filed with the Securities and Exchange Commission on December 13, 2021

As filed with the Securities and Exchange Commission on December 13, 2021 Registration No.

As filed with the Securities and Exchange Commission on December 13, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Forward Pharma A/

As filed with the Securities and Exchange Commission on December 13, 2021 Registration No.

Form of Stand Alone Stock Option Award Agreement.

Exhibit 4.4 FORWARD PHARMA A/S Option Agreement This Option Agreement (this "Agreement") is made and entered into effective as of , 20 by and between Forward Pharma A/S, company registration no. (CVR no.) 28865880, a public limited liability company duly incorporated and organized under the laws of the Kingdom of Denmark (the "Company"), and , an employee of the Company (the "Participant"). Grant

Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statement of Financial Position as of June 30, 2021 and December 31, 2020

Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements Interim Condensed Consolidated Statement of Financial Position as of June 30, 2021 and December 31, 2020 Assets ? ? ? ? ? ? ? ? ? ? ? June 30, ? ? ? ? ? ? 2021 ? December 31, ? ? ? ? (Unaudited) ? 2020 ? Notes USD `000 USD `000 Non-current assets: ? ? ? ? ? ? Other non-current assets ? 3 3 Total non-current assets 3 3 Prepa

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 12, 2021 Commission File Number: 001-36686 Forward Pharma A/S Østerga

Table of Contents ? FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 October 12, 2021 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover F

Six Months Ended June 30,

? Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with the unaudited interim condensed consolidated financial statements, including the notes thereto, included elsewhere in this Report on Form 6-K, as well as our Annual Report on For

Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing

EXHIBIT 99.1 Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?we,? ?Forward? or the ?Company?), today announced that the Technical Board of Appeal (the ?TBA?) of the European Patent Office (the ?EPO?) has dismissed Forward?s ap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 6, 2021 Commission File Number: 001-36686 Forwa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 6, 2021 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports unde

Unaudited Interim Condensed Consolidated Statement of Profit or Loss for the six-month periods ended June 30, 2021 and 2020 amounts in thousands except per share amounts

Exhibit 99.2 Unaudited Interim Condensed Consolidated Statement of Profit or Loss for the six-month periods ended June 30, 2021 and 2020 amounts in thousands except per share amounts Six Months Ended June 30, 2021 2020 USD USD Research and development costs (63 ) (235 ) General and administrative costs (1,761 ) (1,788 ) Operating loss (1,824 ) (2,023 ) Foreign exchange rate gain (loss), net 893 (2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 31, 2021 (Commission file number) Forward Pharma A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 31, 2021 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

Interim Condensed Consolidated Statement of Financial Position as of June 30, 2021, Unaudited, and December 31, 2020

Exhibit 99.1 Interim Condensed Consolidated Statement of Financial Position as of June 30, 2021, Unaudited, and December 31, 2020 Assets June 30, 2021 (Unaudited) December 31, 2020 USD `000 USD `000 Non-current Assets: Other non-current assets 3 3 Total non-current assets 3 3 Prepaid expenses 224 337 Other receivables 182 91 Income tax receivable 190 196 Cash and cash equivalents 75,097 79,087 Tot

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 2, 2021 Commission File Number: 001-36686 Forward Pharma A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 2, 2021 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 21, 2021 Commission File Number: 001-36686 Forward Pharma A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 21, 2021 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 27, 2021 (Commission file number) Forward Pharma A/S

6-K 1 f6k052721.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 27, 2021 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of

RESULTS OF 2021 ANNUAL MEETING OF SHAREHOLDERS

Exhibit 99.1 RESULTS OF 2021 ANNUAL MEETING OF SHAREHOLDERS The annual general meeting of the shareholders of Forward Pharma A/S (the ?Company?) was held on May 27, 2021 at the Company?s offices, ?stergade 24A, 1, 1100 Copenhagen K, Denmark (the ?Annual Meeting?). DKK 815,850.44 of the Company's share capital and 81,585,044 votes, respectively, were represented at the Annual Meeting. Results of th

Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Thursday 27 May 2021 at 2:00 pm (CET). Name: Address: Name: Address: (P l e as e u s e CA PI T A L L ET TE

Exhibit 99.2 Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Thursday 27 May 2021 at 2:00 pm (CET). Name: Address: Name: Address: (P l e as e u s e CA PI T A L L ET TE R S ) I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below: Please ch

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 3, 2021 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover of F

Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Thursday 27 May 2021 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Cop

Exhibit 99.1 Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Thursday 27 May 2021 at 2.00 pm (CET) at the company?s premises, ?stergade 24A, 1st floor, 1100 Copenhagen K, Denmark. AGENDA (a) The board of directors? report on the company?s activities in the past financial year. (b) Presentation an

If you wish to give proxy or vote by correspondence, please complete the proxy/voting by correspondence form. Please remember to sign and date the form. Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S wil

Exhibit 99.3 If you wish to give proxy or vote by correspondence, please complete the proxy/voting by correspondence form. Please remember to sign and date the form. Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S will be held on Thursday 27 May 2021 at 2 . 00 pm (CET) at the company?s premises, ?stergade 24 A, 1 st floor, 1100 Copenhagen K, Denmark .

AKTIER OG STEMMERETTIGHEDER PR. 3. MAJ 2021 * Stemmerettigheder kan ikke udøves AKTIER NOMINEL VÆRDI (DKK) ANTAL AKTIER (Á NOMINELT DKK 0,01) ANTAL STEMMER Aktier 982.644,29 98.264.429 98.264.429 Udstedte aktier 982.644,29 98.264.429 98.264.429 Egne

Exhibit 99.4 SHARES AND VOTING RIGHTS AS PER 3 MAY 2021 * Voting rights cannot be exercised SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.01) NO. OF VOTES Ordinary shares 982,644.29 98,264,429 98,264,429 Outstanding shares 982,644.29 98,264,429 98,264,429 Own holding of shares* 0 0 0 Outstanding shares excluding own holding of shares 982,644.29 98,264,429 98,264,429 AKTIER OG STEMME

Forward Pharma Corporate Update (Nasdaq:FWP) April 15, 2021 2021© Forward Pharma A/S Forward - Looking Statements 2 2021© Forward Pharma A/S Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S w

Exhibit 99.1 Forward Pharma Corporate Update (Nasdaq:FWP) April 15, 2021 2021? Forward Pharma A/S Forward - Looking Statements 2 2021? Forward Pharma A/S Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include, but are not limited to,

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 15, 2021 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

two filings

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 15, 2021 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDT?GTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

English translation of Amended and Restated Articles of Association, dated April 13, 2021.

Exhibit 1.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text. In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail. VEDT?GTER FOR FORWARD PHARMA A/S CVR-NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR-NO. 28865880 1 NAVN OG FORM?L NA

Consent of EY Godkendt Revisionspartnerselskab, Independent Registered Public Accounting Firm.

EX-15.1 7 a2243179zex-151.htm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-203313) pertaining to the Forward Pharma A/S 2014 Omnibus Equity Incentive Compensation Plan of our report dated April 14, 2021, with respect to the consolidated financial statements of Forward Pharm

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the ?Company?), on Form 20-F for the fiscal year ended December 31, 2020 as filed with the Securities and Exchange Commission (the ?Report?), I, Claus Bo Svendsen, Chief Executive Officer, principal executive

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

Exhibit 12.1 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

Our Annual Report on Form 20-F for the year ended December 31, 2020 filed with the Commission on April 14, 2021;

Use these links to rapidly review the document TABLE OF CONTENTS Forward Pharma A/S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

Exhibit 12.2 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)*

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* forward pharma a/s (Name of Issuer) AMERICAN DEPOSITARY SHARES, EACH REPRESENTING FOURTEEN ORDINARY SHARES, NOMINAL VALUE 0.01 (Title of Class of Securities) 34986J204 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value 0.01 DKK per share (Title of Class of Securities) 34986J204 (CUSIP Numb

Forward Pharma Corporate Update (Nasdaq:FWP) January 12, 2021 2021© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer Forward - Looking Statements 2 2021© Forward Pharma A/S Certain statements in this presentation may constitute “

Exhibit 99.2 Forward Pharma Corporate Update (Nasdaq:FWP) January 12, 2021 2021© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer Forward - Looking Statements 2 2021© Forward Pharma A/S Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 12, 2021 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under

Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions

EXHIBIT 99.1 Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appea

Interim Condensed Consolidated Statement of Financial Position as of June 30, 2020, Unaudited, and December 31, 2019

Exhibit 99.1 Interim Condensed Consolidated Statement of Financial Position as of June 30, 2020, Unaudited, and December 31, 2019 Assets June 30, 2020 (Unaudited) December 31, 2019 USD `000 USD `000 Non-current Assets: Other non-current assets 3 2 Total non-current assets 3 2 Prepaid expenses 128 292 Other receivables 187 95 Income tax receivable 179 178 Cash and cash equivalents 75,626 77,598 Tot

Unaudited Interim Condensed Consolidated Statement of Profit or Loss for the six-month periods ended June 30, 2020 and 2019 amounts in thousands except per share amounts

Exhibit 99.2 Unaudited Interim Condensed Consolidated Statement of Profit or Loss for the six-month periods ended June 30, 2020 and 2019 amounts in thousands except per share amounts Six Months Ended June 30, 2020 2019 USD USD Research and development costs (235 ) (626 ) General and administrative costs (1,788 ) (2,602 ) Operating loss (2,023 ) (3,228 ) Foreign exchange rate (loss) gain (240 ) 187

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 11, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 11, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

Forward Pharma Investor Slides ( Nasdaq:FWP ) September 11, 2020 2020© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking stat

Exhibit 99.1 Forward Pharma Investor Slides ( Nasdaq:FWP ) September 11, 2020 2020© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements i

Current Report of Foreign Issuer - FORM 6-K

6-K 1 f6k060420.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 4, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of

Forward Pharma Investor Slides (Nasdaq:FWP) June 3, 2020 2020© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer Forward - Looking Statements 2 2020© Forward Pharma A/S Certain statements in this presentation may constitute “forwa

Exhibit 99.1 Forward Pharma Investor Slides (Nasdaq:FWP) June 3, 2020 2020© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer Forward - Looking Statements 2 2020© Forward Pharma A/S Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - loo

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 3, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDTÆGTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 20, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM

Exhibit 99.2 Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Thursday 4 June 2020 at 2:00 pm (CET). Name: Address: (Please use CAPITAL LETTERS) I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below: Please check off field A), B), C) or D)

Annual General Meeting in Forward Pharma A/S

Exhibit 99.3 Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S will be held on Thursday 4 June 2020 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark. REQUEST FOR ADMISSION CARD Access to the annual general meeting is conditional on the shareholder having requested an admission card by Friday 29 May 2020 end

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 May 12, 2020 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover of

NO. OF SHARES (OF NOMINALLY DKK 0.01)

Exhibit 99.4 SHARES AND VOTING RIGHTS AS PER 12 MAY 2020 SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.01) NO. OF VOTES Ordinary shares 950,738.64 95,073,864 95,073,864 Outstanding shares 950,738.64 95,073,864 95,073,864 Own holding of shares* 0 0 0 Outstanding shares excluding own holding of shares 950,738.64 95,073,864 95,073,864 * Voting rights cannot be exercised AKTIER OG STEMM

Thursday 4 June 2020 at 2.00 pm (CET)

Exhibit 99.1 Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Thursday 4 June 2020 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark. AGENDA (a) The board of directors’ report on the company’s activities in the past financial year. (b) Presentation an

Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19

EXHIBIT 99.1 Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19 COPENHAGEN, Denmark, May 12, 2020 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to current precautionary measures against the spread of the novel coronavirus (“COVID-19”), the Technical Board of Appeal (the “TBA”) of the European Patent O

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2020 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cov

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 29, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDTÆGTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

Forward Pharma Investor Slides ( Nasdaq:FWP ) April 27, 2020 2020© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statemen

Exhibit 99.1 Forward Pharma Investor Slides ( Nasdaq:FWP ) April 27, 2020 2020© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements inclu

Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 27, 2020 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

Letter Agreement between the Registrant and The Bank of New York Mellon, as depositary, dated May 29, 2019.

Exhibit 2.3 Depositary Receipts 240 Greenwich Street 22nd Floor New York, NY 10286 May 29, 2019 Claus Bo Svendsen, MD, PhD Chief Executive Officer Forward Pharma A/S Ostergade 24A,1 1100 Copenhagen K Denmark Dear Dr. Svendsen, This letter agreement (the “Agreement”) confirms our fees and expenses for depositary services between The Bank of New York Mellon as Depositary (the “Depositary”) and by Fo

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

Exhibit 12.2 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the “Company”), on Form 20-F for the fiscal year ended December 31, 2019 as filed with the Securities and Exchange Commission (the “Report”), I, Claus Bo Svendsen, Chief Executive Officer, principal executive

Consent of Ernst & Young P/S, Independent Registered Public Accounting Firm.

Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-203313) pertaining to the Forward Pharma A/S 2014 Omnibus Equity Incentive Compensation Plan of our report dated April 24, 2020, with respect to the consolidated financial statements of Forward Pharma A/S included in this Annual Report (

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

Exhibit 12.1 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

- 20-F

Use these links to rapidly review the document TABLE OF CONTENTS Index to the Consolidated Financial Statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Description of Securities.

Exhibit 2.6 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Set forth below is a summary of certain information concerning our share capital as well as a description of certain provisions of our Articles of Association and relevant provisions of the Danish Companies Act (“DCA”). Because the following is only a summary, it does not contain all of the inf

FWP / Forward Pharma A/S / Biotechnology Value Fund L P - AMENDMENT NO. 3 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value 0.01 DKK per share (Title of Class of Securities) 34986J204 (CUSIP Numb

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated February 14, 2020 with respect to the Ordinary shares of Forward Pharma A/S, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securi

FWP / Forward Pharma A/S / Newtyn Management, LLC - INITIAL FILING Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* forward pharma a/s (Name of Issuer) AMERICAN DEPOSITARY SHARES, EACH REPRESENTING FOURTEEN ORDINARY SHARES, NOMINAL VALUE 0.01 (Title of Class of Securities) 34986J204 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement)

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 23, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 13, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDTÆGTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares

EXHIBIT 99.1 Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares (“ADSs”), issued by the Bank of N

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 26, 2019 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports unde

Forward Pharma ( Nasdaq:FWP ) Investor Slides September 11, 2019 2019© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 3 Investment Highlights ▪ Business optimized to support ongoing IP strategy and continuing obligations per Se

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Investor Slides September 11, 2019 2019© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements i

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 11, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 10, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

Interim Condensed Consolidated Statement of Financial Position as of June 30, 2019, Unaudited, and December 31, 2018

Exhibit 99.1 Interim Condensed Consolidated Statement of Financial Position as of June 30, 2019, Unaudited, and December 31, 2018 Assets June 30, 2019 (Unaudited) December 31, 2018 USD `000 USD `000 Non-current Assets: Other non-current assets 2 2 Total non-current assets 2 2 Prepaid expenses 168 340 Other receivables 153 266 Income tax receivable 181 182 Cash and cash equivalents 80,169 82,542 To

Unaudited Interim Condensed Consolidated Statement of Profit or Loss for the six-month periods ended June 30, 2019 and 2018 amounts in thousands except per share amounts

Exhibit 99.2 Unaudited Interim Condensed Consolidated Statement of Profit or Loss for the six-month periods ended June 30, 2019 and 2018 amounts in thousands except per share amounts Six-Month Periods Ended June 30, 2019 2018 USD USD Research and development costs (626 ) (1,843 ) General and administrative costs (2,602 ) (5,803 ) Operating loss (3,228 ) (7,646 ) Foreign exchange rate gain 187 1,85

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 22, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange

EXHIBIT 99.1 Forward Pharma A/S Announces Intention to Transfer its U.S. Public Listing to the Nasdaq Capital Market Stock Exchange COPENHAGEN, Denmark, June 26, 2019 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (the “Company”) today announced its intention to transfer its public listing of American Depositary Shares from the Nasdaq Global Select Market to the Nasdaq Capital Market. This fol

FWP / Forward Pharma A/S 6-K - Current Report of Foreign Issuer - FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 21, 2019 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under co

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDTÆGTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

FWP / Forward Pharma A/S 6-K Current Report of Foreign Issuer FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 10, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

FWP / Forward Pharma A/S 6-K Current Report of Foreign Issuer FORM 6-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 8, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office) I

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k041519.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 April 15, 2019 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file

Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM

Exhibit 99.2 Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Wednesday 8 May 2019 at 2:00 pm (CET). Name: Address: (Please use CAPITAL LETTERS) I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below: Please check off field A), B), C) or D)

Annual General Meeting in Forward Pharma A/S

Exhibit 99.1 Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Wednesday 8 May 2019 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark. AGENDA (a) The board of directors’ report on the company’s activities in the past financial year. (b) Presentation an

NO. OF SHARES (OF NOMINALLY DKK 0.01)

Exhibit 99.4 SHARES AND VOTING RIGHTS AS PER 15 APRIL 2019 SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.01) NO. OF VOTES Ordinary shares 950,738.64 95,073,864 95,073,864 Outstanding shares 950,738.64 95,073,864 95,073,864 Own holding of shares* 0 0 0 Outstanding shares excluding own holding of shares 950,738.64 95,073,864 95,073,864 * Voting rights cannot be exercised AKTIER OG STE

Annual General Meeting in Forward Pharma A/S

Exhibit 99.3 Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S will be held on Wednesday 8 May 2019 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark. REQUEST FOR ADMISSION CARD Access to the annual general meeting is conditional on the shareholder having requested an admission card by Friday 3 May 2019 end

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 April 9, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

Forward Pharma ( Nasdaq:FWP ) Investor Slides April 9, 2019 2019© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 3 Investment Highlights ▪ Business optimized to support ongoing IP strategy and continuing obligations per Settlem

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Investor Slides April 9, 2019 2019© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements includ

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

QuickLinks - Click here to rapidly navigate through this document Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the "Company"), on Form 20-F for the fiscal year ended December 31, 2018 as filed with the Securities and Exchange Commission (the "Report"),

Consent of Ernst & Young P/S, Independent Registered Public Accounting Firm.

QuickLinks - Click here to rapidly navigate through this document Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-203313) pertaining to the Forward Pharma A/S 2014 Omnibus Equity Incentive Compensation Plan of our report dated April 4, 2019, with respect to the consolidated financial

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

QuickLinks - Click here to rapidly navigate through this document Exhibit 12.2 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance

FWP / Forward Pharma A/S 20-F

Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

QuickLinks - Click here to rapidly navigate through this document Exhibit 12.1 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 March 25, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

FWP / Forward Pharma A/S / Biotechnology Value Fund L P - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value 0.10 DKK per share (Title of Class of Securities) 34986J105 (CUSIP Numb

Forward Pharma ( Nasdaq:FWP ) Investor Slides January 15, 2019 2019© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statem

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Investor Slides January 15, 2019 2019© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements inc

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k011519.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 15, 2019 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Addres

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 26, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

Forward Pharma ( Nasdaq:FWP ) Investor Slides November 26, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking state

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Investor Slides November 26, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements in

Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference

EXHIBIT 99.1 Forward Pharma Provides Update on the Decision of the Federal Circuit in its Appeal of the U.S. Patent Interference The U.S. Court of Appeals for the Federal Circuit has affirmed the decision of the Patent Trial and Appeal Board in the U.S. patent interference proceeding The appeal of the European EP2801355 patent opposition continues Forward expects to reduce operating expenses to ma

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2018 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under

Forward Pharma ( Nasdaq:FWP ) Corporate Update October 2, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statem

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Corporate Update October 2, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements inc

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 1, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 25, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

Forward Pharma ( Nasdaq:FWP ) Corporate Update September 25, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking sta

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Corporate Update September 25, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements

FWP / Forward Pharma A/S 6-K (Current Report of Foreign Issuer)

Table of Contents FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 19, 2018 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover F

The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall pr

Exhibit 99.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text . In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail . VEDTÆGTER FOR FORWARD PHARMA A/S CVR - NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR - NO. 28865880 1 NAVN OG FO

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 18, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 29, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

Forward Pharma ( Nasdaq:FWP ) Corporate Update August 30, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statem

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Corporate Update August 30, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements inc

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 30, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 7, 2018 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cove

Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent

Exhibit 99.2 Forward Pharma Appeals the Decision of the Opposition Division to Revoke the EP2801355 Patent COPENHAGEN, Denmark, May 07, 2018 (GLOBE NEWSWIRE) - Forward Pharma A/S (Nasdaq:FWP) (“We” or “Forward” or the “Company”), today announced the filing of a notice of appeal of the decision of the Opposition Division of the European Patent Office (the “EPO”) that revoked EP2801355 (the “’355 pa

Forward Pharma ( Nasdaq:FWP ) Corporate Update May 7, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements

EXHIBIT 99.1 Forward Pharma ( Nasdaq:FWP ) Corporate Update May 7, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include

FWP / Forward Pharma A/S / Biotechnology Value Fund L P - AMENDMENT NO. 1 TO THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value 0.10 DKK per share (Title of Class of Securities) 34986J105 (CUSIP Numb

Wednesday 30 May 2018 at 2.00 pm (CET)

Exhibit 99.1 Annual General Meeting in Forward Pharma A/S Notice to convene Annual General Meeting The annual general meeting in Forward Pharma A/S will be held on Wednesday 30 May 2018 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark. agenda (a) The board of directors’ report on the company’s activities in the past financial year. (b) Presentation a

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of May 2018 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports un

Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM

Exhibit 99.2 Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Wednesday 30 May 2018 at 2:00 pm (CET). Name: Address: (Please use CAPITAL LETTERS) I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below: Please check off field A), B), C) or D

NO. OF SHARES (OF NOMINALLY DKK 0.01)

Exhibit 99.4 Shares and voting rights as per 1 May 2018 SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.01) NO. OF VOTES Ordinary shares 943,679.98 94,367,998 94,367,998 Outstanding shares 943,679.98 94,367,998 94,367,998 Own holding of shares* 0 0 0 Outstanding shares excluding own holding of shares 943,679.98 94,367,998 94,367,998 * Voting rights cannot be exercised

Annual General Meeting in Forward Pharma A/S

Exhibit 99.3 Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S will be held on Wednesday 30 May 2018 at 2.00 pm (CET) at the company’s premises, Østergade 24A, 1st floor, 1100 Copenhagen K, Denmark. Request for admission card Access to the annual general meeting is conditional on the shareholder having requested an admission card by Friday 25 May 2018 en

Forward Pharma ( Nasdaq:FWP ) Corporate Update May 1, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements

Exhibit 99.1 Forward Pharma ( Nasdaq:FWP ) Corporate Update May 1, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k050118.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of

FWP / Forward Pharma A/S 20-F

Use these links to rapidly review the document TABLE OF CONTENTS Forward Pharma A/S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Consent of Ernst & Young P/S, Independent Registered Public Accounting Firm.

QuickLinks - Click here to rapidly navigate through this document Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-203313) pertaining to the Forward Pharma A/S 2014 Omnibus Equity Incentive Compensation Plan of our report dated April 30, 2018, with respect to the consolidated financial

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

QuickLinks - Click here to rapidly navigate through this document Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the "Company"), on Form 20-F for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission (the "Report"),

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

QuickLinks - Click here to rapidly navigate through this document Exhibit 12.2 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as amended.

QuickLinks - Click here to rapidly navigate through this document Exhibit 12.1 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstance

VEDTÆGTER FORWARD PHARMA A/S CVR-NR. 28865880

Exhibit 99.1 VEDTÆGTER FOR FORWARD PHARMA A/S CVR-NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR-NO. 28865880 1 NAVN OG FORMÅL NAME AND OBJECTS 1.1 Selskabets navn er Forward Pharma A/S. The name of the company is Forward Pharma A/S. 1.2 Selskabets formål er direkte eller indirekte via datterselskaber at drive aktiviteter med udvikling, fremstilling, distribution og salg af lægemid

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal exe

Forward Pharma ( NASDAQ:FWP ) Corporate Update February 13, 2018 2018© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking stat

Exhibit 99.1 Forward Pharma ( NASDAQ:FWP ) Corporate Update February 13, 2018 2018? Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements i

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 February 13, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

FWP / Forward Pharma A/S / Baupost Group LLC/MA - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 01)* Forward Pharma A/S (Name of Issuer) Common Stock (Title of Class of Securities) 34986J105 (CUSIP Number) January 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2018 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual

Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent Forward Pharma Expects to Appeal the Decision Upon Review

EdgarFiling EXHIBIT 99.1 Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent Forward Pharma Expects to Appeal the Decision Upon Review COPENHAGEN, Denmark, Jan. 29, 2018 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?Forward? or the ?Company?) today announced that the European Patent Office (the ?EPO?) has revoked the EP2

Forward Pharma ( NASDAQ:FWP ) Corporate Presentation January 5, 2018 2018© Forward Pharma A/S 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meanin

Exhibit 99.1 Forward Pharma ( NASDAQ:FWP ) Corporate Presentation January 5, 2018 2018? Forward Pharma A/S 2 Forward - Looking Statements Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include, but are not limited to, statements whic

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 January 5, 2018 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

FWP / Forward Pharma A/S / Biotechnology Value Fund L P - THE SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Forward Pharma A/S (Name of Issuer) Ordinary Shares, nominal value 0.10 DKK per share (Title of Class of Securities) 34986J105 (CUSIP Numbe

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 2, 2018 with respect to the Shares of Forward Pharma A/S, and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchan

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 21, 2017 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports unde

Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit Oral argument expected in second or third quarter of 2018

EdgarFiling EXHIBIT 99.1 Forward Pharma Files Final Brief in its Appeal of the U.S. Patent Interference to the Federal Circuit Oral argument expected in second or third quarter of 2018 COPENHAGEN, Denmark, Dec. 21, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?Forward? or the ?Company?) today announced the filing of its reply brief to the U.S. Court of Appeals for the Federal Circuit (

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 4, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

Amended and Restated Articles of Association, dated November 28, 2017.

Exhibit 99.1

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 December 4, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

Forward Pharma ( NASDAQ:FWP ) Corporate Update December 5, 2017 2017© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking state

Exhibit 99.1 Forward Pharma ( NASDAQ:FWP ) Corporate Update December 5, 2017 2017? Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements in

Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018

EdgarFiling EXHIBIT 99.1 Forward Pharma Files Further Written Submissions in the European Opposition Proceeding for the EP2801355 Patent in Preparation for the Oral Hearing in January 2018 COPENHAGEN, Denmark, Nov. 29, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?Forward? or the ?Company?) today announced the filing of further written submissions in the European Opposition Proceeding

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k112917.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 29, 2017 Commission File Number: 001-36686 Forward Pharma A/S Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k112417.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 24, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Addre

Forward Pharma ( NASDAQ:FWP ) Corporate Presentation November 24, 2017 2017© Forward Pharma A/S 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the mean

Exhibit 99.1 Forward Pharma ( NASDAQ:FWP ) Corporate Presentation November 24, 2017 2017? Forward Pharma A/S 2 Forward - Looking Statements Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include, but are not limited to, statements wh

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 22, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

SIGNATURE PAGE FOLLOWS

Exhibit 99.3 File no.: 1022720/2454 Pledge agreement concerning the shares in FWP IP ApS File no.: 1022720/2454 This Pledge AGREEMENT (the ?Agreement?) is made on 22 November 2017 by FWP HoldCo ApS Registration no. (CVR no. ) ?stergade 24A, 1. 1100 Copenhagen K Denmark (?HoldCo?) Biogen Swiss Manufacturing GmbH Landys & Gyr Strasse 3 6300 Zug Switzerland (?Biogen?) and Forward Pharma A/S Registrat

Forward Pharma Announces Completion of Corporate Restructuring Plan

EdgarFiling Exhibit 99.1 Forward Pharma Announces Completion of Corporate Restructuring Plan COPENHAGEN, Denmark, Nov. 22, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?Forward Pharma?) today announced the completion of its previously announced corporate restructuring plan (the ?Restructuring?) substantially in the form set forth in Appendix D to the Settlement and License Agreement, d

SIGNATURE PAGE FOLLOWS

Exhibit 99.4 SHARE PURCHASE AGREEMENT Between Forward Pharma Operations ApS And FWP HoldCo ApS concerning the shares in FWP IP ApS This SHARE PURCHASE AGREEMENT (the "Agreement") was concluded on 22 November 2017 between Forward Pharma Operations ApS CVR-no. 38 75 75 04 ?stergade 24A, 1. 1100 Copenhagen K (the ?Seller?) and FWP HoldCo ApS CVR-no. ?stergade 24A, 1. 1100 Copenhagen K (the "Buyer") (

SIGNATURE PAGE FOLLOWS

Exhibit 99.2 File no.: 1022720/2454 call option agreement between Biogen Swiss Manufacturing GmbH FWP HoldCo ApS And Forward Pharma A/S concerning the shares in FWP IP ApS File no.: 1022720/2454 This Call Option Agreement (the ?Call Option Agreement?) is made on 22 November 2017 between FWP HoldCo ApS Registration no. (CVR no. ) ?stergade 24A, 1. 1100 Copenhagen K Denmark (?HoldCo?) Biogen Swiss M

Amended and Restated Articles of Association of Forward Pharma A/S, dated November 21, 2017

Exhibit 3.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text. In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail. VEDT?GTER FOR FORWARD PHARMA A/S CVR-NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR-NO. 28865880 1 NAVN OG FORM?L NA

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 21, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive off

FWP / Forward Pharma A/S FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 November 3, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offi

ANTAL AKTIER (Á NOMINELT DKK 0,01)

Exhibit 99.1 Aktier og stemmerettigheder pr. 3. november 2017 AKTIER NOMINEL V?RDI (DKK) ANTAL AKTIER (? NOMINELT DKK 0,01) ANTAL STEMMER Aktier 943.679,98 94.367.998 94.367.998 Udstedte aktier 943.679,98 94.367.998 94.367.998 Egne aktier* 0 0 0 Udstedte aktier fratrukket egne aktier 943.679,98 94.367.998 94.367.998 * Stemmerettigheder kan ikke ud?ves Ekstraordin?r generalforsamling i Forward Phar

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 October 2, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

Forward Pharma ( NASDAQ:FWP ) Corporate Presentation October 2, 2017 2017© Forward Pharma A/S 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meanin

EX-99.1 2 exh991.htm EXHIBIT 99.1 Exhibit 99.1 Forward Pharma ( NASDAQ:FWP ) Corporate Presentation October 2, 2017 2017© Forward Pharma A/S 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looking statements” of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include, but a

SIGNATURE SHEET FOLLOWS

Exhibit 99.1 ASSET CONTRIBUTION AGREEMENT concerning the assets, rights, liabilities and obligations of Forward Pharma A/S CVR no. 28 86 58 80 SCHEDULES Schedule 1.6 Independent Practitioner?s Report Schedule 1.7 Opening Balance Sheet Schedule 2.1 Assets Schedule 2.2.3 Excluded Assets Schedule 3.1 List of Contracts Schedule 5.2 Memorandum of Association Schedule 6.1.1 Assignment Agreement Schedule

Forward Pharma A 6-K (Current Report of Foreign Issuer)

FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 September 26, 2017 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 4

IPR SERVICES, ADMINISTRATION, FUNDING AND NOVATION AGREEMENT

Exhibit 99.2 AGREED FORM IPR SERVICES, ADMINISTRATION, FUNDING AND NOVATION AGREEMENT This IPR SERVICES, ADMINISTRATION, FUNDING AND NOVATION AGREEMENT (this ?Agreement?), effective as of June 30, 2017, is made and entered into between Forward Pharma A/S, a Danish limited liability company (?Forward Pharma?), Forward Pharma Operations ApS, a Danish limited liability company and wholly owned direct

Forward Pharma ( NASDAQ:FWP ) Corporate Presentation September 11, 2017 2017© Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute “forward - looki

Exhibit 99.1 Forward Pharma ( NASDAQ:FWP ) Corporate Presentation September 11, 2017 2017? Forward Pharma A/S Claus Bo Svendsen, MD, PhD Chief Executive Officer 2 Forward - Looking Statements Certain statements in this presentation may constitute ?forward - looking statements? of Forward Pharma A/S within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking state

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 11, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive of

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 5, 2017 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports unde

Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit

EdgarFiling EXHIBIT 99.1 Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit COPENHAGEN, Denmark, Sept. 05, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?Forward? or the ?Company?) today announced the filing in the U.S. Court of Appeals for the Federal Circuit (the ?Federal Circuit?) of the opening brief for the appeal of the PTAB dec

Amended and Restated Articles of Association of Forward Pharma A/S

Exhibit 3.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text. In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail. VEDT?GTER FOR FORWARD PHARMA A/S CVR-NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR-NO. 28865880 1 NAVN OG FORM?L NA

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k090117.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 1, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Addre

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 September 1, 2017 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports unde

Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders

EdgarFiling EXHIBIT 99.1 Forward Pharma Board of Directors Approves Capital Reduction and Returns EUR 917.7 Million to Shareholders COPENHAGEN, Denmark, Sept. 01, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?the Company? or ?Forward?) today announced the final approval by the Company?s board of directors of the plans to return a total of EUR 917.7 million to its shareholders through a

(Updated as of 23 August 2017)

Exhibit 99.1 NOTE This document is intended to provide general answers to some common questions that Forward Pharma A/S (?Forward? or the ?Company?) shareholders may have in connection with Forward?s planned capital reduction and distribution of EUR 19.45 per share. It is not intended to provide legal or tax advice or specific answers relating to questions pertaining to such matters. For such ques

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 23, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive offic

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 4, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

This document is intended to provide general answers to some common questions that Forward Pharma A/S (“Forward” or the “Company”) shareholders may have in connection with Forward’s planned capital reduction and distribution of EUR 19.45 per share. I

Exhibit 99.1 NOTE This document is intended to provide general answers to some common questions that Forward Pharma A/S (?Forward? or the ?Company?) shareholders may have in connection with Forward?s planned capital reduction and distribution of EUR 19.45 per share. It is not intended to provide legal or tax advice or specific answers relating to questions pertaining to such matters. For such ques

Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting

EdgarFiling EXHIBIT 99.1 Forward Pharma Obtains Shareholder Approval of the Planned Capital Reduction at the Extraordinary General Meeting COPENHAGEN, Denmark, Aug. 02, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?the Company? or ?Forward?) today announced the result of the extraordinary general meeting of its shareholders held on August 2, 2017 (the ?Extraordinary General Meeting?),

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 August 2, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office

Amended and Restated Articles of Association of Forward Pharma A/S

Exhibit 3.1 The English part of this parallel document in Danish and English is an unofficial translation of the original Danish text. In the event of disputes or misunderstandings arising from the interpretation of the translation, the Danish language shall prevail. VEDT?GTER FOR FORWARD PHARMA A/S CVR-NR. 28865880 ARTICLES OF ASSOCIATION OF FORWARD PHARMA A/S CBR-NO. 28865880 1 NAVN OG FORM?L NA

EX-99.7

Exhibit 99.7

EX-99.6

Exhibit 99.6

Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders

EdgarFiling EXHIBIT 99.1 Forward Pharma announces planned distribution of EUR 19.45 per share to Shareholders COPENHAGEN, Denmark, July 18, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?the Company? or ?Forward?) today announced plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction. This decision is based on a care

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 July 18, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

EX-99.8

EX-99.8 9 exh998.htm EXHIBIT 99.8 Exhibit 99.8

EX-99.9

Exhibit 99.9

EX-99.2

EX-99.5

Exhibit 99.5

EX-99.3

EX-99.3 4 exh993.htm EXHIBIT 99.3 Exhibit 99.3

EX-99.4

EX-99.4 5 exh994.htm EXHIBIT 99.4 Exhibit 99.4

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 20, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

EX-99.1

Exhibit 99.1

Forward Pharma (NASDAQ:FWP) CorporateUpdate Jefferies 2017 Global HealthcareConference June 6,2017 2017© Forward PharmaA/S. Claus Bo Svendsen, MD,PhD Chief ExecutiveOfficer Forward-LookingStatements 2 2017© Forward PharmaA/S. Certainstatementsinthisp

Exhibit 99.1 Forward Pharma (NASDAQ:FWP) CorporateUpdate Jefferies 2017 Global HealthcareConference June 6,2017 2017? Forward PharmaA/S. Claus Bo Svendsen, MD,PhD Chief ExecutiveOfficer Forward-LookingStatements 2 2017? Forward PharmaA/S. Certainstatementsinthispresentationmayconstitute?forward-lookingstatements?ofForwardPharmaA/S(the ?Company?)withinthemeaningofthePrivateSecuritiesLitigationRefor

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 June 6, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office)

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

6-K 1 f6k050417.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 4, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant’s name into English) Østergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of

EX-99.1

EXHIBIT 99.1

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 3, 2017 001-36686 (Commission file number) Forward Pharma A/S (Translation of registrant?s name into English) ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark (Address of principal executive office) I

Forward Pharma A FORM 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2017 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports under cover o

Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement

EdgarFiling Exhibit 99.1 Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement COPENHAGEN, Denmark, May 01, 2017 (GLOBE NEWSWIRE) - Forward Pharma A/S (NASDAQ:FWP) (?we? or ?Forward? or the ?Company?) today provided an update on the Company?s strategic focus and related initiatives to reduce operating and personnel costs following the Settlement and Lic

Forward Pharma A 6-K (Current Report of Foreign Issuer)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the month of April 2017 Commission File Number: 001-36686 Forward Pharma A/S ?stergade 24A, 1st Floor 1100 Copenhagen K, Denmark Indicate by check mark whether the registrant files or will file annual reports

Forward Pharma A/S Annual Report 2016

Exhibit 99.5 Forward Pharma A/S Annual Report 2016 CVR-nr. 28865880 The Annual Report was presented and adopted at the Annual General Meeting of the Company on 2017 Forward Pharma A/S Index to Annual Report Page GENERAL Management?s statement 3 Independent auditor?s reports 4 Management?s review 6 FINANCIAL STATEMENTS Statement of financial position 7 Statement of profit or loss 8 Statement of com

NOMINAL VALUE (DKK)

Exhibit 99.4 SHARES AND VOTING RIGHTS AS PER 18 APRIL 2017 SHARES NOMINAL VALUE (DKK) NO. OF SHARES (OF NOMINALLY DKK 0.10) NO. OF VOTES Ordinary shares 4,718,399.90 47,183,999 47,183,999 Outstanding shares 4,718,399.90 47,183,999 47,183,999 Own holding of shares* 0 0 0 Outstanding shares excluding own holding of shares 4,718,399.90 47,183,999 47,183,999 * Voting rights cannot be exercised

Annual General Meeting in Forward Pharma A/S

Exhibit 99.3 Annual General Meeting in Forward Pharma A/S The annual general meeting in Forward Pharma A/S will be held on Wednesday 3 May 2017 at 2.00 pm (CET) at the company?s premises, ?stergade 24A, 1st floor, 1100 Copenhagen K, Denmark. REQUEST FOR ADMISSION CARD Access to the annual general meeting is conditional on the shareholder having requested an admission card by Friday 28 April 2017 e

Wednesday 3 May 2017 at 2.00 pm (CET)

Exhibit 99.1 Annual General Meeting in Forward Pharma A/S NOTICE TO CONVENE ANNUAL GENERAL MEETING The annual general meeting in Forward Pharma A/S will be held on Wednesday 3 May 2017 at 2.00 pm (CET) at the company?s premises, ?stergade 24A, 1st floor, 1100 Copenhagen K, Denmark. AGENDA (a) The board of directors? report on the company?s activities in the past financial year. (b) Proposal regard

Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM

Exhibit 99.2 Annual General Meeting in Forward Pharma A/S PROXY/VOTING BY CORRESPONDENCE FORM for use at the annual general meeting in Forward Pharma A/S on Wednesday 3 May 2017 at 2:00 pm (CET). Name: Address: (Please use CAPITAL LETTERS) I/we hereby authorise by proxy/submit written votes (voting by correspondence) in accordance with the indications below: Please check off field A), B), C) or D)

CERTIFICATION

Exhibit 12.1 CERTIFICATION I, Claus Bo Svendsen, certify that: (1) I have reviewed this annual report on Form 20-F of Forward Pharma A/S; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respe

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.2 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the ?Company?), on Form 20-F for the fiscal year ended December 31, 2016 as filed with the Securities and Exchange Commission (the ?Report?), I, Joel Sendek, Chief Financial

CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 13.1 CERTIFICATION BY THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Forward Pharma A/S (the “Company”), on Form 20-F for the fiscal year ended December 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Claus Bo Svendsen, Chief Exe